Finance

Worth Watching Stocks: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) and Crescent Point Energy Corporation (NYSE:CPG)

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company’s pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel’s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)’s Financial Overview

Rigel Pharmaceuticals, Inc. (NASDAQ) declined -0.42% yesterday to close its trading session at $2.39. The company has 1 year Price Target of $8.07. Rigel Pharmaceuticals, Inc. has 52-Week high of $4.71 and 52-Week Low of $1.96. The stock touched its 52-Week High on 4.71 and 52-Week Low on 1.96. The stock traded with the volume of 1.19 Million shares yesterday. The firm shows the market capitalization of $398.29 Million.

Rigel Pharmaceuticals, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.14/share against the analyst consensus estimate of $-0.15/share. The difference between the actual and expected EPS is $0.01 a share with a surprise factor of 6.7%.

The firm is trading with SMA20 of -2.29 Percent, SMA50 of -10.67 Percent and SMA200 of -23.51 percent. Rigel Pharmaceuticals, Inc. has P/S value of 59.45 while its P/B value stands at 3.85. Similarly, the company has Return on Assets of -82.6 percent, Return on Equity of -97.7 percent and Return on Investment of -79.1 Percent. The company shows Gross Margin and Operating Margin of 98.5 percent and 0 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 7 analysts offering 12-month price forecasts for Rigel Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 7.00. The median estimate represents a +234.73% increase from the last price of 2.39.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Crescent Point Energy Corporation (NYSE:CPG)

Crescent Point Energy Corp. is engaged in the acquisition, exploration and development of oil and natural gas properties in Western Canada. The Company’s operations consist of light and medium oil and natural gas assets strategically focused in core areas in southern Saskatchewan and central and southern Alberta. Crescent Point Energy Corp., formerly known as Crescent Point Energy Trust, is headquartered in Calgary, Canada.

Crescent Point Energy Corporation (NYSE:CPG)’s Financial Outlook

The 18 analysts offering 12-month price forecasts for Crescent Point Energy Corp have a median target of 6.44, with a high estimate of 12.50 and a low estimate of 3.73. The median estimate represents a +86.70% increase from the last price of 3.45.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Crescent Point Energy Corporation has a Consensus Recommendation of 2. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 4.55% and closed its last trading session at $3.45. The company has the market capitalization of $1.9 Billion. The stock has 52-week high of $9.25 and 52-Week low of $2.7. The firm touched its 52-Week high on 9.25 and 52-Week low on 2.70. The company has volume of 1.54 Million shares. The company has a total of 550.15 Million shares outstanding.

Crescent Point Energy Corporation (NYSE) in the last quarter reported its actual EPS of $-0.08/share where the analyst estimated EPS was $-0.03/share. The difference between the actual and Estimated EPS is $0. This shows a surprise factor of 0 percent.

The company has YTD performance of 14.24 percent. Beta for Crescent Point Energy Corporation stands at 0 while its ATR (average true range) is 0.22. The company has Weekly Volatility of 5.23%% and Monthly Volatility of 6.98%%.

Crescent Point Energy Corporation has distance from 20-day Simple Moving Average (SMA20) of 11.52%, Distance from 50-Day Simple Moving Average of -4.33 percent and Distance from 200-Day Simple Moving Average of -44.27%.

The Company currently has ROA (Return on Assets) of 0 percent, Return on Equity (ROE) of 0 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.